Volume 34, No 2, Feb 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 2, February 2024: 97-98

RESEARCH HIGHLIGHTS

SUS(d6)pending MHC class I peptide presentation for cancer immunoevasion

Devin Dersh^1,* , Jonathan W. Yewdell^2,*

¹Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
²Cellular Biology Section, Laboratory of Viral Diseases, NIAID, Bethesda, MD, USA
Correspondence: Devin Dersh(ddersh@pennmedicine.upenn.edu)Jonathan W. Yewdell(jyewdell@niaid.nih.gov)

Reported recently in Cell , Chen et al. identify a novel membrane-based inhibitory complex composed of SUSD6 and TMEM127 that targets MHC class I complexes for lysosomal degradation in human and mouse acute myeloid leukemia cells. Ablation of these components enhances tumor immunogenicity, promotes T cell killing, and impairs tumorigenicity in a variety of mouse cancer models.

https://doi.org/10.1038/s41422-023-00882-4

FULL TEXT | PDF

Browse 175